

## Disposal of own shares

**Brussels (Belgium), 5 August 2022 – 20:00 (CEST) – Regulated information**

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long-Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
29 July 2022	16:51:20	Stock Option Plan 2013	200	€ 48,69
01 August 2022	00:00:00	Stock Option Plan 2013	1.000	€ 48,69

In addition to these exercises, on 1 August 2022, in accordance with the vesting rules under its 2019, 2020 and 2021 LTI plan, UCB SA/NV has delivered for free a total of 7 984 UCB shares OTC to 10 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 1 August 2022 was € 79.28.

This press release is available on UCB SA/NV's website via the following [link](#).

---

**For further information, contact UCB:**

**Investor Relations**

Antje Witte  
T +32 2 559 94 14  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

**Corporate Communications**

Laurent Schots  
T+32 2 559 92 64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news